Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
The multifaceted roles of IL-4 and IL-13 in allergic disease development make IL-4Rα an attractive target for treatment strategies, and a neutralizing monoclonal antibody which antagonizes the effects of both IL-4 and IL-13 by blocking the interaction site found in the IL-4 receptor subunit α (IL-4Rα) has been successfully used to treat patients with moderate-to-severe AD.
|
31596502 |
2020 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Relevant literature concerning novel therapeutics for AD beyond targeted monoclonal antibodies antagonizing selectively interleukin (IL)-4 or IL-13 was obtained from a PubMed and clinicaltrials.gov search and summarized.
|
31622669 |
2020 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
This review provides an update on the role of IL-13 in AD and discusses the different strategies aimed at interfering with its biologic activity as well as their potential in a precision medicine approach in the management of AD.
|
31230370 |
2020 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Development of antagonistic antibody (Ab) against interleukin-4 receptor alpha (IL-4Rα) subunit of IL-4/IL-13 receptors is a promising therapeutic strategy for T helper 2 (T<sub>H</sub>2)-mediated allergic diseases such as asthma and atopic dermatitis.
|
31123339 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Notably, SCCAs are induced by IL-4 and IL-13, vital Th2 cytokines that play important roles in AD etiology.
|
31378660 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a monoclonal antibody blocking the action of IL-4 and IL-13 effectively reduces the symptoms of AD and itch.
|
31505056 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
The overlap between the IL-13-stimulated epithelial cell transcriptome and the respective disease transcriptome was 22, 9, and 5% in EoE, AD, and AA, respectively, indicating a greater involvement of the IL-13 pathway in EoE than AA (<i>p</i> = 0.0007) or AD (<i>p</i> = 0.02).
|
31824894 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Decreased levels of IFN-γ (Th1) and IL-17 (Th17), IL-4 and IL-13 (Th2) were detected in T cells and the skin tissue from the MSC-Ex treated AD mice.
|
31036853 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dupilumab (a monoclonal antibody blocking the shared receptor component for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma.
|
31066001 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).
|
30981576 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
In acute lesions of AD, the T-helper type 2 cells produce interleukin (IL) 4, IL-13, and IL-31, which may potentiate barrier dysfunction and contribute to pruritus.
|
31690388 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Biologics targeting IL-13, such as the anti-IL-4Rα antibody dupilumab and the anti-IL-13 antibody tralokinumab, successfully improve AD lesions and further highlight the importance of IL-13 in the pathogenesis of AD.
|
31509236 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Recently, cases of AA healing during treatment with anti-IL4/IL13 monoclonal antibody dupilumab (D) for AD were reported.
|
31306557 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Rare coding variants associated with AD are further enriched in 5 genes (IL-4 receptor [IL4R], IL13, Janus kinase 1 [JAK1], JAK2, and tyrosine kinase 2 [TYK2]) of the IL13 pathway, all of which are targets for novel systemic AD therapeutics.
|
31707051 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dupilumab [a monoclonal antibody blocking the shared receptor subunit for interleukin (IL)-4 and IL-13] is approved for the treatment of patients with inadequately controlled, moderate-to-severe AD.
|
31407311 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Although the presence of maternal atopic dermatitis (AD) was associated with increased gestational IL-13 concentrations [adj.
|
31428082 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
The Th2 (IL-13) and Th22-related products (IL-22, S100A8/9/12) and serum IgE were significantly correlated with clinical severity (Scoring of Atopic Dermatitis [SCORAD]) in AA.
|
30223113 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis.
|
30641038 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this study, we used keratinocytes and AD-like skin equivalent models using Th2 cytokines IL-4 and IL-13.
|
30506356 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Among potential targets, interleukin 13 (IL-13) merits consideration, as monoclonal antibodies disrupting IL-13 signaling are proving to be exceedingly effective in common conditions such as atopic dermatitis.
|
30759882 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a fully human monoclonal antibody that binds IL-4Rα and inhibits signaling of both IL-4 and IL-13, has shown efficacy across multiple diseases with underlying type 2 signatures and is approved for treatment of asthma, atopic dermatitis and chronic sinusitis with nasal polyposis.
|
31838750 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a monoclonal antibody that blocks the shared receptor subunit for interleukin (IL)-4 and IL-13, is currently approved for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD).
|
31424712 |
2019 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Tralokinumab treatment was associated with early and sustained improvements in AD symptoms and an acceptable safety and tolerability profile, thereby providing evidence for targeting IL-13 in patients with AD.
|
29906525 |
2019 |
Dermatitis, Atopic
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We also investigated the inhibitory capacity of WIKIM30 on the development of 2,4-dinitrochlorobenzene-induced atopic dermatitis (AD), a Th2-dominant allergic disease in mice.Oral administration of <i>L. sakei</i> WIKIM30 significantly reduced AD-like skin lesions and serum immunoglobulin E and IL-4 levels while decreasing the number of CD4<sup>+</sup> T cells and B cells and the levels of Th2 cytokines (IL-4, IL-5, and IL-13) in peripheral lymph nodes and enhancing Treg differentiation and IL-10 secretion in mesenteric lymph nodes.
|
30154801 |
2018 |
Dermatitis, Atopic
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a fully human monoclonal antibody targeting the interleukin (IL)-4 receptor α, thereby blocking the IL-4 and IL-13 pathway, is one of the first biologics that has been developed for AD.
|
30181845 |
2018 |